Patients with type 2 diabetes
Conditions
Sponsors
Ise Red Cross Hospital Department of Metabolic Diseases
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Outpatients 2) Inadequate glucose control even after dietary and exercise therapies for more than 8 weeks 3) No previous administration of pioglitazone as an oral hypoglycemic drug 4) 6.5% more than fasting HbA1c under 10% 5) fasting blood glucose levels greater than 110mg/dl and under 250mg/dl 6) Patients who themselves can voluntarily provide consent to participate in this study, and can also follow the study protocol
Exclusion criteria
Exclusion criteria: 1) type 1 diabetes 2) secondary diabetes 3) Patients receiving insulin or GLP-1 analogue therapy 4) Poor-controlled diabetes (HbA1c>10.0 % or fasting blood glucose levels greater than 250mg/dl) 5) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months 6) Either level of aspartate aminotransaminase or alanine aminotransferase exceed three-fold of the normal limits 7) renal insufficiency: serum creatinine>1.5 8) Malignancies or other diseases with poor prognosis 9) Pregnant 10) Subjects whose doctor in charge do not agree to join the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Flow mediated dilation (FMD) | — |
Secondary
| Measure | Time frame |
|---|---|
| Hemoglobin A1C levels, pre/postprandial blood glucose/lipids levels, BMI, adiponectin, ADMA, mean IMT, mean ba-PWV | — |
Countries
Japan
Contacts
Public ContactSatoshi Ida
Ise Red Cross Hospital Department of Metabolic Diseases
Outcome results
None listed